Valeant Pharmaceuticals International (NYSE:VRX) (TSX:VRX) and Anacor Pharmaceuticals (NASDAQ:ANAC) have reached a final $142.5 million settlement to put a series of spats to rest, including allegations of intellectual property infringement, shared confidential information, and broken contracts.
Anacor had previously announced a $100 million settlement from Valeant for issues originating from its newly acquired subsidiary Dow Pharmaceutical Sciences, but this latest announcement also includes settlement for dispute over a research and development pact with Valeant business unit Medicis Pharmaceutical.
Valeant has agreed to pay Anacor its settlement no later than Nov. 8.
The Motley Fool recommends Valeant Pharmaceuticals. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.